19733-96-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(6-methylpyridin-3-yl)acetic acid is used as a chemical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its unique structure allows it to be a key component in the development of new medications, enhancing the therapeutic potential of pharmaceutical products.
Used in Research and Development:
In the realm of scientific research, 2-(6-methylpyridin-3-yl)acetic acid serves as a valuable compound for the exploration and development of new drugs and pharmaceuticals. Its properties make it a promising candidate for studying its effects on biological systems and its potential role in treating various diseases and conditions.
While the provided materials do not specify the exact applications or industries where 2-(6-methylpyridin-3-yl)acetic acid is used beyond the pharmaceutical industry and research, its classification as a phenylacetic acid suggests that it may have potential uses in other areas such as chemical synthesis, material science, or as a building block for other organic compounds. Further research and development would be necessary to explore these possibilities.

InChI:InChI=1/C8H9NO2/c1-6-2-3-7(5-9-6)4-8(10)11/h2-3,5H,4H2,1H3,(H,10,11)

Upstream product

• 36357-38-7 1-(6-methyl-pyridin-3-yl)-ethanone 
• 3430-13-5 5-bromo-2-methylpyridine 
• 5470-70-2 Methyl 6-methylnicotinate 
• 90610-06-3 (6-methyl-pyridin-3-yl)-acetic acid methyl ester 
• 19733-95-0 4-[(6-methyl-pyridin-3-yl)-thioacetyl]-morpholine 

Downstream Products

• 1229621-59-3 N-(4-methylphenyl)-2-(6-methylpyridin-3-yl)acetamide 
• 21241-10-1 4-methyl-N-(2-(6-methylpyridin-3-yl)ethyl)aniline 
• 21241-09-8 4-methyl-N-[2-(6-methylpyridin-3-yl)ethyl]-N-nitrosoaniline 
• 100189-17-1 2-(6-methylpyridin-3-yl) ethan-1-ol 
• 1229621-60-6 N'-(1-methyl-piperidin-4-ylidene)-N-[2-(6-methyl-pyridin-3-yl)-ethyl]-N-p-tolyl-hydrazine 
• 21241-08-7 2-methyl-5-{2-[1-(4-methylphenyl)hydrazinyl]ethyl}pyridine 
• 3613-73-8 dimebon 
• 91843-27-5 ethyl (6-methylpyridin-3-yl)acetate 

Relevant academic research and scientific papers

SALT INDUCIBLE KINASE INHIBITORS

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES

The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.

Tetraaza-cyclopenta[a]indenyl derivatives

The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.

SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Y4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE

The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.

Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives

The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.

AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS

The invention relates to compounds of formula (I), wherein R, R1, m, n and X1to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention

SYNTHESIS OF 9-(ARYLALKYL)-1,2,3,4-TETRAHYDRO-Υ-CARBOLINE AND ANALOGUES AND INTERMEDIATES

The present invention pertains generally to methods of preparing certain 9-(arylalkyl)- 1,2,3,4-tetrahydro-Υ-carboline compounds and their analogues, and especially to methods of preparing dimebon. The present invention also pertains to methods of preparing certain intermediate compounds which find use in the synthesis of the 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline compounds.

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk